The British Business Bank (BBB), the UK government's development bank, made a £50m cornerstone commitment to Longwall Ventures Fund 4 on Wednesday 27 May, through its Enterprise Capital Funds programme1. Longwall 4 targets £100m and had reached £86.2m at announcement. The fund writes £500,000 to £2m cheques into 14 to 16 early-stage deeptech firms across advanced manufacturing, clean energy, defence and life sciences. Longwall's first fund backed OrganOx, the Oxford organ-perfusion company sold to Japan's Terumo in 2025 for more than $1.5bn, a 19.2x return for the Bank2.
This is the bottom of a barbell, and it is where the Headline numbers come apart. UK venture funding reached $10.5bn in January to April 2026, double the same period last year, according to data firm GlobalData3. Yet deal volume fell 2%, and more than 40% of that money sits in three rounds: Nscale, Wayve and Ineffable. A 2% drop in deal count against a doubling of capital means the money pooled into fewer, larger rounds while most founders saw nothing change. The cash concentrated at the top; the count thinned underneath it.
The Bank backed Longwall because the £500,000 to £2m tier has lost its private anchor. Venture Capital Trust relief, the retail-investor tax incentive that historically funded that band, was cut from 30% to 20% on 6 April, and no institution replaced the angels it supported. Meanwhile the BBB's own £6.6bn direct mandate has been deploying upward into Series A and beyond all spring, with £40m into Quantum Motion, £12m into Cytospire and £13m into Elliptic. Government capital is now occupying both ends at once: cornerstoning the seed-tier floor while its sovereign vehicles chase the AI mega-rounds, with no instrument addressing the Series B middle that thins between them.
